The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
At StockStory, we look beyond the headlines with our independent analysis to determine whether these bullish calls are justified. That said, here are three stocks where Wall Street’s estimates seem disconnected from reality and some better opportunities to consider.
Consensus Price Target: $13.50 (21.2% implied return)
Based in Jacksonville, Florida, Redwire (NYSE:RDW) is a provider of systems and components used in space infrastructure.
Why Are We Wary of RDW?
Historically negative EPS is a worrisome sign for conservative investors and obscures its long-term earnings potential
Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 28.2 percentage points
Depletion of cash reserves could lead to a fundraising event that triggers shareholder dilution
Redwire is trading at $11.14 per share, or 1,649.4x forward EV-to-EBITDA. Dive into our free research report to see why there are better opportunities than RDW.
Consensus Price Target: $54 (32.3% implied return)
Established in 1987, Silgan Holdings (NYSE:SLGN) is a supplier of rigid packaging for consumer goods products, specializing in metal containers, closures, and plastic packaging.
Why Are We Out on SLGN?
Sales trends were unexciting over the last two years as its 4.1% annual growth was below the typical industrials company
Projected sales growth of 2.6% for the next 12 months suggests sluggish demand
Gross margin of 16.8% is below its competitors, leaving less money to invest in areas like marketing and R&D
At $40.81 per share, Silgan Holdings trades at 10.8x forward P/E. To fully understand why you should be careful with SLGN, check out our full research report (it’s free).
Consensus Price Target: $104 (33% implied return)
With a nationwide footprint spanning 671 clinics across 42 states, U.S. Physical Therapy (NYSE:USPH) operates a network of outpatient physical therapy clinics and provides industrial injury prevention services to employers across the United States.
Why Do We Think Twice About USPH?
Modest revenue base of $781 million gives it less fixed cost leverage and fewer distribution channels than larger companies
Incremental sales over the last five years were less profitable as its 1.9% annual earnings per share growth lagged its revenue gains
Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 6 percentage points